EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY-NC 4.0

Hematopoietic effects of tagraxofusp in treatment‐naive patients with blastic plasmacytoid dendritic cell neoplasm

Marina Konopleva, Naveen Pemmaraju iD, Kendra L Sweet, Anthony S Stein, David A Rizzieri, Eunice S Wang iD, Sumithira Vasu, Todd Rosenblat, Michael Zuurman, Ira Gupta, Andrew A Lane

Cancer · 01.01.2026 · 132 (1)

DOI: 10.1002/cncr.70243 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, online erschienen am 04.01.2026. Verfasst von Marina Konopleva und 10 weiteren Autor:innen. Beteiligte Einrichtung: Albert Einstein College of Medicine/Montefiore Cancer Center, Bronx, New York, USA. Hauptthemen laut MEDLINE: Dendritic Cells, Hematologic Neoplasms, Recombinant Fusion Proteins, Hematopoiesis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Menarini Group.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic neoplasm that expresses CD123, is often observed in the bone marrow (BM), as well as skin, blood, and viscera. Tagraxofusp, a first‐in‐class CD123‐targeted therapy, is the only drug approved to treat BPDCN.

Methods

The authors conducted a post hoc analysis of the pivotal phase 2 trial to evaluate hematopoietic and BM effects of first‐line tagraxofusp treatment (12 µg/kg per day on days 1–5 of a 21‐day cycle) over time. This trial was registered at www.clinicaltrials.gov (ClinicalTrials.gov identifier NCT02113982).

Results

Of 66 treatment‐naive patients in this analysis, 32 had baseline BM disease, and 34 had no BM disease. Over the course of tagraxofusp monotherapy treatment, neutrophil levels restored to normal, mirrored by a decreasing incidence of neutropenia and granulocyte‐colony–stimulating factor administration from baseline with each cycle of treatment. Similarly, platelet counts recovered during treatment, whereas thrombocytopenia incidence and requirement for platelet transfusions decreased from baseline. Hemoglobin levels improved during tagraxofusp treatment, correlating with a decrease in the incidence of anemia and the number of transfusions from baseline. By cycle 2, all patients had peripheral blast clearance regardless of BM status. Patients with BM disease who did or did not achieve a complete response/clinical complete response during treatment experienced similar restoration of hematopoiesis, including peripheral blast eradication.

Conclusions

These findings demonstrate the on‐target effect and unique BM‐sparing profile of tagraxofusp, which are paramount when treating myelosuppressive, CD123‐positive hematologic diseases. The results support single‐agent tagraxofusp as standard‐of‐care, nonmyelosuppressive first‐line treatment for BPDCN and as a potential combination partner for other CD123‐positive hematologic malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dendritic CellsHematologic NeoplasmsRecombinant Fusion ProteinsHematopoiesisHumansMaleFemaleMiddle AgedAgedAdultInterleukin-3 Receptor alpha SubunitAged, 80 and overBlastic Plasmacytoid Dendritic Cell Neoplasm

Stichwörter der Autor:innen

blastic plasmacytoid dendritic cell neoplasmbone marrow sparingfirst‐linehematopoietic effectsside effects, tagraxofusptreatment‐naive

Substanzen

tagraxofuspRecombinant Fusion ProteinsInterleukin-3 Receptor alpha Subunit

Autor:innen und Institutionen

  • Albert Einstein College of Medicine/Montefiore Cancer Center, Bronx, New York, USA.
  • The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Moffitt Cancer Center, Tampa, Florida, USA.
  • City of Hope, Duarte, California, USA.
  • Novant Health Cancer Institute, Charlotte, North Carolina, USA.
  • Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

ORCID-Profile: Naveen Pemmaraju, Eunice S Wang

Förderung

  • Menarini Group

Zitieren

APA

Konopleva, M., Pemmaraju, N., Sweet, K. L., Stein, A. S., Rizzieri, D. A., Wang, E. S., Vasu, S., Rosenblat, T., Zuurman, M., Gupta, I., & Lane, A. A. (2026). Hematopoietic effects of tagraxofusp in treatment‐naive patients with blastic plasmacytoid dendritic cell neoplasm. Cancer, 132(1). https://doi.org/10.1002/cncr.70243

Vancouver

Konopleva M, Pemmaraju N, Sweet KL, Stein AS, Rizzieri DA, Wang ES, et al. Hematopoietic effects of tagraxofusp in treatment‐naive patients with blastic plasmacytoid dendritic cell neoplasm. Cancer. 2026;132(1). doi:10.1002/cncr.70243

BibTeX
@article{Konopleva2026,
  author = {Konopleva, Marina and Pemmaraju, Naveen and Sweet, Kendra L and Stein, Anthony S and Rizzieri, David A and Wang, Eunice S and Vasu, Sumithira and Rosenblat, Todd and Zuurman, Michael and Gupta, Ira and Lane, Andrew A},
  title = {Hematopoietic effects of tagraxofusp in treatment‐naive patients with blastic plasmacytoid dendritic cell neoplasm},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {1},
  doi = {10.1002/cncr.70243}
}
Kostenlos starten →